VANCOUVER, BC, Nov. 10, 2021 /CNW/ - Sirona Biochem Corp. (TSXV:
SBM) (FSE: ZSB) (OTC: SRBCF) ("Sirona") is
pleased to announce the voting results from its Annual General
Meeting of Shareholders (the "Meeting"), held in Vancouver, British Columbia on November 10, 2021. The total number of shares
represented by shareholders present in person and by proxy at the
meeting was 33,335,079, representing 14.45% of Sirona's issued and
outstanding Common Shares.
All matters put forward to shareholders for consideration and
approval, as set out in the Company's Management Information
Circular dated 12th of October, 2021, were approved by
the requisite majority of votes cast at the Meeting. These
were:
1. To elect Sirona's board of directors; 2. to fix the
number of directors of the Company at five; 3. to appoint DeVisser
Gray LLP, Chartered Professional Accountants, as the Company's
auditor for the ensuing year and authorize the directors to set the
auditor's remuneration; and 4. to confirm and approve the Company's
existing stock option plan.
"We thank our shareholders for their participation and continued
support," said Dr. Howard Verrico,
CEO of Sirona. "We look forward to further building and
commercializing our pipeline."
About Sirona Biochem Corp.
Sirona Biochem is a cosmetic ingredient and drug discovery
company with a proprietary platform technology. Sirona specializes
in stabilizing carbohydrate molecules with the goal of improving
efficacy and safety. New compounds are patented for maximum revenue
potential.
Sirona's compounds are licensed to leading companies around the
world in return for licensing fees, milestone fees and ongoing
royalty payments. Sirona's laboratory, TFChem, is located in
France and is the recipient of
multiple French national scientific awards and European Union and
French government grants. For more information, please visit
www.sironabiochem.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Sirona Biochem cautions you that statements included in this
press release that are not a description of historical facts may be
forward-looking statements. Forward-looking statements are only
predictions based upon current expectations and involve known and
unknown risks and uncertainties. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of release of the relevant information, unless
explicitly stated otherwise. Actual results, performance or
achievement could differ materially from those expressed in, or
implied by, Sirona Biochem's forward-looking statements due to the
risks and uncertainties inherent in Sirona Biochem's business
including, without limitation, statements about: the progress and
timing of its clinical trials; difficulties or delays in
development, testing, obtaining regulatory approval, producing and
marketing its products; unexpected adverse side effects or
inadequate therapeutic efficacy of its products that could delay or
prevent product development or commercialization; the scope and
validity of patent protection for its products; competition from
other pharmaceutical or biotechnology companies; and its ability to
obtain additional financing to support its operations. Sirona
Biochem does not assume any obligation to update any
forward-looking statements except as required by law.
SOURCE Sirona Biochem Corp.